Loading
Life sciences · Journal article
Talanta · September 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Amyloid-beta 42 (Aβ42) is a core biomarker associated with Alzheimer's disease (AD), but accurate quantification of low-abundance plasma Aβ42 remains challenging because of matrix interference, limited assay sensitivity, and time-consuming procedures in conventional methods. Herein, we developed an enzyme-free fluorescence biosensing platform integrating a triple-helix aptamer probe (THAP) with clamped hybridization chain reaction (cHCR), termed T-cHCR, for sensitive Aβ42 analysis. In this system, Aβ42 recognition induces controlled release of a trigger probe from the triplex-locked THAP module, which subsequently initiates a two-hairpin cHCR cascade for low-background signal amplification. Under optimized conditions, the T-cHCR assay exhibited a linear response to Aβ42 from 1 to 1000 pg/mL with a limit of detection of 1.16 pg/mL, showing an 8.1-fold lower LOD than the manufacturer-reported minimum detectable dose of the ELISA kit used in this study. The assay also displayed acceptable specificity, reproducibility, and storage stability. Preliminary analysis of clinical plasma samples showed significantly different Aβ42 levels between AD patients and age-matched healthy controls, supporting the potential of T-cHCR for further validation in plasma AD biomarker analysis. Overall, this integrated THAP-cHCR strategy provides a rapid, enzyme-free, and low-background approach for ultrasensitive plasma Aβ42 detection.